The Journey of Atorvastatin

Atorvastatin is administered as the calcium salt of its open-acid
form. It is absorbed primarily in the small intestine through passive diffusion and organic anion
transporting polypeptide (OATP)-mediated uptake. Absolute bioavailability is low — only 12% of
an oral dose reaches systemic circulation — due to extensive first-pass hepatic extraction (the
desired pharmacokinetic behavior, since the liver is the target organ). The gastrointestinal
absorption itself is approximately 30-40% efficient. Food modestly reduces Cmax but does not affect
overall AUC substantially, so atorvastatin can be taken without regard to meals. Peak plasma
concentration occurs at 1-2 hours. Unlike older statins (lovastatin, simvastatin), atorvastatin is
administered as the active acid form, not a prodrug lactone.

After intestinal absorption, atorvastatin enters portal blood
and is extensively extracted by the liver, mediated primarily by OATP1B1 (encoded by SLCO1B1) and
OATP1B3 on hepatocyte basolateral membranes. Hepatic first-pass extraction approaches 80-90%.
Plasma protein binding exceeds 98% (albumin and alpha-1-acid glycoprotein). Volume of distribution
is large (381 L), reflecting tissue distribution beyond plasma. Atorvastatin penetrates adipose
tissue but CNS penetration is minimal due to its high molecular weight and lipophilicity combined
with P-glycoprotein efflux at the blood-brain barrier. This CNS selectivity is beneficial — it
reduces the risk of neurological side effects compared to earlier, more lipophilic statins.

Atorvastatin and its active metabolites (ortho- and para-hydroxy
atorvastatin, each pharmacologically equipotent with the parent) competitively inhibit
HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase), the enzyme catalyzing the
rate-limiting, irreversible step in cholesterol biosynthesis: conversion of HMG-CoA to mevalonate.
The statin's dihydroxyheptanoic acid moiety mimics the transition-state structure of HMG-CoA,
binding with nanomolar affinity to the active site. Reduced intracellular cholesterol synthesis
in hepatocytes triggers two compensatory responses: upregulation of LDL receptor expression
(via SREBP-2 transcription factor activation) and upregulation of PCSK9 (which paradoxically
accelerates LDL receptor degradation, partially blunting the benefit — a reason PCSK9 inhibitors
add to statin benefit). The net result is a 25-55% reduction in plasma LDL-C depending on dose.
Pleiotropic effects include anti-inflammatory properties (reduced hs-CRP), endothelial function
improvement, and plaque stabilization independent of lipid lowering.

Atorvastatin undergoes extensive hepatic metabolism primarily
by CYP3A4 (with minor contributions from CYP3A5) to ortho-hydroxy atorvastatin and para-hydroxy
atorvastatin, both of which retain HMG-CoA reductase inhibitory activity equivalent to the parent
compound, contributing approximately 70% of the overall pharmacological effect. Further metabolism
produces inactive beta-oxidation products. Because CYP3A4 is also the primary enzyme for many
other drugs and is inhibited by a wide range of substances (grapefruit juice, azole antifungals,
macrolide antibiotics, HIV protease inhibitors), atorvastatin has numerous clinically significant
drug interactions. CYP3A4 inhibition increases atorvastatin AUC up to 10-fold with strong inhibitors
like itraconazole, dramatically increasing myopathy risk.

Atorvastatin and its metabolites are excreted primarily via bile
into feces (approximately 70%) with less than 2% appearing unchanged in urine. Hepatic metabolism
followed by biliary secretion (mediated by ABCB1/P-gp and ABCG2 on canalicular hepatocyte membranes)
is the dominant elimination pathway. Plasma half-life of atorvastatin is 14 hours, but the
pharmacodynamic half-life for cholesterol suppression is much longer (20-30 hours) because of
the active metabolites. Unlike some statins, atorvastatin does not require dose adjustment in
renal impairment since renal excretion is minimal.

Atorvastatin reduces major cardiovascular events by 36% in primary
prevention (ASCOT-LLA) and by 22% per 1 mmol/L LDL reduction in secondary prevention. SLCO1B1
polymorphisms reducing OATP1B1 function (*5 allele, rs4149056) increase plasma exposure up to
200% and raise myopathy risk substantially — pharmacogenomic testing may guide dose selection.
Myopathy risk (0.1-0.5%) increases with high doses, renal impairment, hypothyroidism, and
concurrent CYP3A4 inhibitors. Rarely, immune-mediated necrotizing myopathy with anti-HMGCR
antibodies persists after statin discontinuation.